{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:03:25Z","timestamp":1790946205578,"version":"4.1.0"},"reference-count":50,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>An exploratory end point from a recent trial in patients with newly diagnosed multiple myeloma showed that median progression-free survival (PFS) was increased by 10.7 months with denosumab vs zoledronic acid. We performed additional analyses to identify factors that may have contributed to the favorable PFS with denosumab. Ad hoc analyses were performed for patients intending to undergo autologous stem cell transplantation (ASCT; ASCT intent), not intending to undergo ASCT (ASCT no intent), and intent-to-treat according to age (&amp;lt;70 or \u226570 years) and baseline renal function (\u226460 mL\/min or &amp;gt;60 mL\/min creatinine clearance [CrCl]). Of 1718 patients, 930 (54.1%) were in the ASCT-intent subgroup, and 788 (45.9%) were in the ASCT-no-intent subgroup. In the ASCT-intent subgroup, frontline triplet (median PFS, not estimable vs 35.7 months; hazard ratio [HR] [95% confidence interval (CI)], 0.65 [0.47-0.90]; descriptive P = .009) or bortezomib-only (median PFS, not estimable vs not estimable; HR [95% CI], 0.61 [0.39\u20130.95]; descriptive P = .029) induction regimens demonstrated the strongest PFS benefit favoring denosumab vs zoledronic acid. In the ASCT-no-intent subgroup, no benefit with denosumab vs zoledronic acid was observed. PFS favored denosumab vs zoledronic acid in patients with CrCl &amp;gt;60 mL\/min and in patients &amp;lt;70 years old, but no difference was observed in patients with CrCl \u226460 mL\/min or patients \u226570 years old. The PFS difference observed with denosumab is one of the notable benefits reported in newly diagnosed multiple myeloma and was most pronounced in patients intending to undergo ASCT and those who received proteasome inhibitor (PI)\u2212based triplet regimens. This study was registered at www.clinicaltrials.gov as #NCT01345019.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020002378","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T02:28:45Z","timestamp":1612405725000},"page":"725-736","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":41,"title":["Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study"],"prefix":"10.1182","volume":"5","author":[{"given":"Evangelos","family":"Terpos","sequence":"first","affiliation":[{"name":"Department of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noopur","family":"Raje","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA;"},{"name":"Center for Multiple Myeloma, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Croucher","sequence":"additional","affiliation":[{"name":"Garvan Institute of Medical Research, Sydney, NSW, Australia;"},{"name":"Faculty of Medicine, St Vincent\u2019s Clinical School, UNSW Sydney, Sydney, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Garcia-Sanz","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[{"name":"Department of Hematology, H\u00f4pital La Mileterie, Poitiers, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waltraud","family":"Pasteiner","sequence":"additional","affiliation":[{"name":"Amgen, Inc., Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[{"name":"Amgen, Inc., Thousand Oaks, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Glennane","sequence":"additional","affiliation":[{"name":"Amgen, Inc., Thousand Oaks, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jude","family":"Canon","sequence":"additional","affiliation":[{"name":"Amgen, Inc., Thousand Oaks, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Pawlyn","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,2,2]]},"reference":[{"issue":"12","key":"2021020216343962500_B1","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study","volume":"5","author":"Fitzmaurice","year":"2019","journal-title":"JAMA Oncol"},{"issue":"4","key":"2021020216343962500_B2","first-page":"285","article-title":"Myeloma bone disease: pathogenesis and treatment","volume":"15","author":"O\u2019Donnell","year":"2017","journal-title":"Clin Adv Hematol Oncol"},{"issue":"1","key":"2021020216343962500_B3","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.4081\/hr.2018.7401","article-title":"Bone-targeted agents in multiple myeloma","volume":"10","author":"Nishida","year":"2018","journal-title":"Hematol Rep"},{"issue":"14","key":"2021020216343962500_B4","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2018-11-852459","article-title":"Myeloma bone disease: from biology findings to treatment approaches","volume":"133","author":"Terpos","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2021020216343962500_B5","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1359\/JBMR.041131","article-title":"Fracture risk with multiple myeloma: a population-based study","volume":"20","author":"Melton","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2021020216343962500_B6","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/leu.2010.62","article-title":"Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease","volume":"24","author":"Terpos","year":"2010","journal-title":"Leukemia"},{"issue":"3","key":"2021020216343962500_B7","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/leu.2008.336","article-title":"Pathogenesis of myeloma bone disease","volume":"23","author":"Roodman","year":"2009","journal-title":"Leukemia"},{"issue":"20","key":"2021020216343962500_B8","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1073\/pnas.201394498","article-title":"Multiple myeloma disrupts the TRANCE\/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression","volume":"98","author":"Pearse","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"13","key":"2021020216343962500_B9","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","article-title":"Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment","volume":"98","author":"Giuliani","year":"2001","journal-title":"Blood"},{"issue":"10","key":"2021020216343962500_B10","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/nm.2452","article-title":"Evidence for osteocyte regulation of bone homeostasis through RANKL expression","volume":"17","author":"Nakashima","year":"2011","journal-title":"Nat Med"},{"issue":"11","key":"2021020216343962500_B11","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1359\/jbmr.2002.17.11.2068","article-title":"MLO-Y4 osteocyte-like cells support osteoclast formation and activation","volume":"17","author":"Zhao","year":"2002","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2021020216343962500_B12","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2141.2004.05018.x","article-title":"Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation","volume":"126","author":"Lai","year":"2004","journal-title":"Br J Haematol"},{"issue":"13","key":"2021020216343962500_B13","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1182\/blood.V98.13.3534","article-title":"Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma","volume":"98","author":"Croucher","year":"2001","journal-title":"Blood"},{"issue":"4","key":"2021020216343962500_B14","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1182\/blood-2010-04-279760","article-title":"Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration","volume":"117","author":"Moreaux","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2021020216343962500_B15","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2003-11-3839","article-title":"Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion","volume":"104","author":"Abe","year":"2004","journal-title":"Blood"},{"issue":"6","key":"2021020216343962500_B16","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1158\/0008-5472.CAN-03-1131","article-title":"Cancer and the microenvironment: myeloma-osteoclast interactions as a model","volume":"64","author":"Yaccoby","year":"2004","journal-title":"Cancer Res"},{"issue":"3","key":"2021020216343962500_B17","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"issue":"6","key":"2021020216343962500_B18","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3816\/CLM.2009.n.085","article-title":"Serum levels of total-RANKL in multiple myeloma","volume":"9","author":"Jakob","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"1","key":"2021020216343962500_B19","doi-asserted-by":"crossref","first-page":"8983","DOI":"10.1038\/ncomms9983","article-title":"Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche","volume":"6","author":"Lawson","year":"2015","journal-title":"Nat Commun"},{"issue":"18","key":"2021020216343962500_B20","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021020216343962500_B21","volume-title":"NCCN Clinical Practice Guidelines in Oncology. Multiple Myeloma","author":"National Comprehensive Cancer Network","year":"2019"},{"issue":"9757","key":"2021020216343962500_B22","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"2021020216343962500_B23","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"2021020216343962500_B24","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00520-013-2022-1","article-title":"Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors","volume":"22","author":"Henry","year":"2014","journal-title":"Support Care Cancer"},{"issue":"9768","key":"2021020216343962500_B25","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"35","key":"2021020216343962500_B26","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"issue":"23","key":"2021020216343962500_B27","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1182\/blood-2011-02-297325","article-title":"International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation","volume":"117","author":"Cavo","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2021020216343962500_B28","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1365-2141.2006.06356.x","article-title":"Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma","volume":"135","author":"Terpos","year":"2006","journal-title":"Br J Haematol"},{"issue":"3","key":"2021020216343962500_B29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1600-0609.2006.00692.x","article-title":"Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment","volume":"77","author":"Heider","year":"2006","journal-title":"Eur J Haematol"},{"issue":"1","key":"2021020216343962500_B30","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.bbrc.2005.05.098","article-title":"Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function","volume":"333","author":"Zavrski","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"2021020216343962500_B31","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/sj.leu.2404806","article-title":"Bortezomib inhibits human osteoclastogenesis","volume":"21","author":"von Metzler","year":"2007","journal-title":"Leukemia"},{"issue":"11","key":"2021020216343962500_B32","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1172\/JCI16198","article-title":"Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro","volume":"111","author":"Garrett","year":"2003","journal-title":"J Clin Invest"},{"issue":"2","key":"2021020216343962500_B33","first-page":"491","article-title":"Pharmacologic targeting of a stem\/progenitor population in vivo is associated with enhanced bone regeneration in mice","volume":"118","author":"Mukherjee","year":"2008","journal-title":"J Clin Invest"},{"issue":"7","key":"2021020216343962500_B34","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.exphem.2014.03.005","article-title":"Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro","volume":"42","author":"Bolomsky","year":"2014","journal-title":"Exp Hematol"},{"issue":"12","key":"2021020216343962500_B35","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/leu.2008.235","article-title":"The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed\/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis [published correction appears in Leukemia. 2008;22:2292]","volume":"22","author":"Terpos","year":"2008","journal-title":"Leukemia"},{"issue":"4","key":"2021020216343962500_B36","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/leu.2013.267","article-title":"VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT","volume":"28","author":"Terpos","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"2021020216343962500_B37","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.0902-4441.2005.t01-1-EJH2520.x","article-title":"First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma","volume":"76","author":"Tosi","year":"2006","journal-title":"Eur J Haematol"},{"issue":"5","key":"2021020216343962500_B38","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.bone.2005.10.004","article-title":"Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells","volume":"38","author":"Humphrey","year":"2006","journal-title":"Bone"},{"issue":"1","key":"2021020216343962500_B39","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/ajh.23577","article-title":"The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed\/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group","volume":"89","author":"Terpos","year":"2014","journal-title":"Am J Hematol"},{"issue":"14","key":"2021020216343962500_B40","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2021020216343962500_B41","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI115305","article-title":"Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma","volume":"88","author":"Bataille","year":"1991","journal-title":"J Clin Invest"},{"issue":"6","key":"2021020216343962500_B42","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrc.2016.44","article-title":"Bone metastasis: the importance of the neighbourhood","volume":"16","author":"Croucher","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2021020216343962500_B43","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1359\/jbmr.2003.18.3.482","article-title":"Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival","volume":"18","author":"Croucher","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2021020216343962500_B44","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2141.2010.08141.x","article-title":"Advances in the understanding of myeloma bone disease and tumour growth","volume":"149","author":"Yaccoby","year":"2010","journal-title":"Br J Haematol"},{"issue":"4","key":"2021020216343962500_B45","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","article-title":"A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer","volume":"12","author":"Body","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2021020216343962500_B46","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/ijc.24758","article-title":"The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation","volume":"126","author":"Guenther","year":"2010","journal-title":"Int J Cancer"},{"issue":"1","key":"2021020216343962500_B47","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/cncr.21104","article-title":"Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect","volume":"104","author":"Corso","year":"2005","journal-title":"Cancer"},{"issue":"1","key":"2021020216343962500_B48","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1006\/bbrc.1999.1499","article-title":"Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates","volume":"264","author":"van Beek","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"2021020216343962500_B49","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ajh.21509","article-title":"An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma","volume":"84","author":"Vij","year":"2009","journal-title":"Am J Hematol"},{"issue":"10068","key":"2021020216343962500_B50","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/3\/725\/1798758\/advancesadv2020002378.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/3\/725\/1798758\/advancesadv2020002378.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T02:29:05Z","timestamp":1612405745000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/3\/725\/475058\/Denosumab-compared-with-zoledronic-acid-on-PFS-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,2]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,2,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020002378","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,2]]}}}